Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2010 2
2011 2
2012 1
2013 1
2014 2
2015 3
2016 2
2017 1
2018 3
2019 6
2020 7
2021 11
2022 12
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Pathology in Practice.
Wu CY, Ramos SJ, Watanabe TTN, Woodward MC, Dehghanpir SD, Rutherford SJ, Pucheu-Haston CM. Wu CY, et al. Among authors: ramos sj. J Am Vet Med Assoc. 2022 Mar 12;259(S2):1-4. doi: 10.2460/javma.20.04.0220. J Am Vet Med Assoc. 2022. PMID: 35349473 Free article.
Pathology in Practice.
Ramos SJ, Kirejczyk SGM, Foglia CL, Bateman FL. Ramos SJ, et al. J Am Vet Med Assoc. 2018 Oct 15;253(8):997-1000. doi: 10.2460/javma.253.8.997. J Am Vet Med Assoc. 2018. PMID: 30272524 Free article. No abstract available.
In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.
Wise MC, Xu Z, Tello-Ruiz E, Beck C, Trautz A, Patel A, Elliott ST, Chokkalingam N, Kim S, Kerkau MG, Muthumani K, Jiang J, Fisher PD, Ramos SJ, Smith TR, Mendoza J, Broderick KE, Montefiori DC, Ferrari G, Kulp DW, Humeau LM, Weiner DB. Wise MC, et al. Among authors: ramos sj. J Clin Invest. 2020 Feb 3;130(2):827-837. doi: 10.1172/JCI132779. J Clin Invest. 2020. PMID: 31697648 Free PMC article.
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, Morrow MP, Pezzoli P, McMullan T, Kulkarni AJ, Zaidi FI, Frase D, Liaw K, Smith TRF, Ramos SJ, Ervin J, Adams M, Lee J, Dallas M, Shah Brown A, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM, Boyer JD, Mammen MP. Kraynyak KA, et al. Among authors: ramos sj. J Infect Dis. 2022 Jun 1;225(11):1923-1932. doi: 10.1093/infdis/jiac016. J Infect Dis. 2022. PMID: 35079784 Free PMC article. Clinical Trial.
54 results